Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September:

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Stepped Up Clinical Efforts Targeting Breast Cancer Therapies and Treatments Leading to Opportunistic Options

, /PRNewswire/ -- Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
ORTX : 4.21 (-4.75%)
HTBX : 1.2500 (-2.34%)
SRPT : 143.20 (-0.56%)
BMY : 59.71 (+0.37%)
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

, /PRNewswire/ --   – In the fight against some of the most challenging forms of cancer, (NYSE:AZN) recently placed a giant  on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
MRK : 82.76 (-0.20%)
IMMU : 85.52 (+0.19%)
AZN : 54.75 (-1.37%)
PFE : 36.39 (+0.94%)
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently ...

AZN : 54.75 (-1.37%)
IMMU : 85.52 (+0.19%)
PFE : 36.39 (+0.94%)
MRK : 82.76 (-0.20%)
ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40 Annual Growth Conference....

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended . All dollar amounts are expressed in Canadian...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

, /PRNewswire/ --   – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...

RHHBY : 44.1100 (-1.58%)
XYNO : 2.7800 (unch)
CANF : 1.7200 (-0.58%)
ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
GNPX : 3.35 (-0.59%)
CRDF : 12.18 (+7.03%)
MRK : 82.76 (-0.20%)
LLY : 148.10 (-1.44%)
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

and , /PRNewswire/ --

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
PFE : 36.39 (+0.94%)
LLY : 148.10 (-1.44%)
NVTA : 43.90 (-1.72%)
CLVS : 6.03 (+2.47%)
CORT : 17.34 (+1.46%)
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

and , /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
PFE : 36.39 (+0.94%)
Oncolytics Biotech® Establishes New At-The-Market Facility

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on . The call focused on recently...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of two abstracts in...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that , President & CEO of...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from...

ONCY : 1.6900 (+1.20%)
ONC.TO : 2.26 (unch)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar